Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14197690 | 0.92 | CACNA1H (0.49) | CACNA1HEPHX1DRD2ALDH1A1KMT2A | |
| SCHEMBL13635148 | 0.86 | DRD2 (0.48) | CACNA1HEPHX1DRD2KMT2AGAA | |
| SCHEMBL13635147 | 0.86 | CACNA1H (0.47) | CACNA1HEPHX1DRD2KMT2AGAA | |
| SCHEMBL18233688 | 0.84 | DRD2 (0.46) | CACNA1HEPHX1DRD2KMT2AGAA | |
| SCHEMBL6007685 | 0.84 | SLC6A1 (0.46) | CACNA1HEPHX1DRD2KMT2AMEN1 | |
| SCHEMBL6007677 | 0.84 | SLC6A1 (0.46) | CACNA1HEPHX1DRD2KMT2AMEN1 | |
| SCHEMBL26003617 | 0.83 | CACNA1H (0.51) | CACNA1HEPHX1DRD2ALDH1A1KMT2A | |
| SCHEMBL16480069 | 0.83 | CACNA1H (0.54) | CACNA1HEPHX1DRD2 | |
| SCHEMBL24172673 | 0.82 | DRD2 (0.56) | CACNA1HEPHX1DRD2KMT2AGAA | |
| SCHEMBL31301250 | 0.82 | DRD2 (0.56) | CACNA1HEPHX1DRD2KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010516-A1 | Novel piperidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010516-A1 | Novel piperidine derivatives | UTS2R, VIPR2, NTSR2 | CACNA1H 1051/4885EPHX1 1555/4885DRD2 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.